Operator
Good morning, ladies and gentlemen, and welcome to the Capricor Therapeutics HOPE-3 Phase III Topline Data Call. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference over to our host, Mr. AJ Bergmann, Capricor’s Chief Financial Officer. Please go ahead.
Anthony Bergmann
CFO & Corporate Treasurer
Thank you, and good morning, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today’s presentation. Statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our enrollment in patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, potential regulatory inspections, revenue and reimbursement estimates, projected terms of definitive agreements, manufacturing capabilities, potential milestone payments, our financial position and our possible uses of existing cash and investment resources.
These forward-looking statements
